What does an indeterminate result for high-risk Human Papillomavirus (HPV) on a sample read mean?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Understanding an Indeterminate Result for High-Risk HPV Testing

An indeterminate result for high-risk HPV on a sample read indicates that the test could not conclusively determine whether high-risk HPV types are present, requiring follow-up testing in 2-4 months to establish a definitive result.

What is High-Risk HPV Testing?

High-risk HPV testing is a screening method that detects the presence of oncogenic (cancer-causing) HPV types in cervical cells. According to the National Comprehensive Cancer Network (NCCN):

  • The FDA-approved HPV DNA test detects whether any of 13-14 high-risk HPV types are present (types 16,18,31,33,35,39,45,51,52,56,58,59, and 68) 1
  • These high-risk types are associated with the development of cervical cancer and precancerous lesions 1
  • The test does not specify which particular high-risk type is present in a standard screening 1

Causes of Indeterminate Results

An indeterminate result can occur for several reasons:

  • Insufficient sample quantity or quality
  • Technical issues during sample processing
  • Presence of interfering substances
  • Borderline viral load that falls between positive and negative detection thresholds

Management of Indeterminate HPV Results

The management approach for indeterminate high-risk HPV results follows these steps:

  1. Repeat testing in 2-4 months - This is the recommended approach for indeterminate results 2
  2. Do not assume the result is negative - An indeterminate result should not be interpreted as truly negative, as it may reflect an inadequate sample 2
  3. Follow age-appropriate screening guidelines for the repeat test

Risk Assessment and Follow-up

The risk assessment depends on additional factors:

  • If cytology (Pap test) is also available and normal: Follow up with repeat co-testing in 2-4 months 3
  • If cytology shows abnormalities: Management should follow the appropriate algorithm based on the cytologic finding 1
  • If HPV genotyping was performed and HPV 16/18 is positive: Referral for colposcopy is recommended regardless of cytology results 2

Clinical Implications

The clinical significance of an indeterminate result should be understood in context:

  • HPV infections are extremely common, with approximately 90% clearing naturally within 1-2 years 3
  • Persistent high-risk HPV infection is the primary risk factor for developing cervical precancer and cancer 4
  • The risk of high-grade cervical intraepithelial neoplasia (CIN II+) is significantly lower with negative HPV results (0.2-0.4%) compared to positive results (5.7%) 5, 2

Important Considerations

  • Do not delay follow-up: While the risk of high-grade lesions is low with indeterminate results followed by negative results, timely follow-up is essential
  • Patient counseling: Explain that an indeterminate result is not uncommon and does not necessarily indicate disease
  • Documentation: Clearly document the indeterminate result and the follow-up plan in the medical record

Common Pitfalls to Avoid

  • Misinterpreting indeterminate as negative: This could lead to delayed diagnosis of significant lesions
  • Causing unnecessary anxiety: Avoid alarming language when discussing results with patients
  • Immediate colposcopy referral: This is not necessary for indeterminate results alone and would lead to unnecessary procedures 3
  • Extended delay in follow-up: Studies show compliance with the recommended 2-4 month follow-up is often low (45.1%), which can lead to missed diagnoses 2

By following these evidence-based guidelines for managing indeterminate high-risk HPV results, clinicians can ensure appropriate follow-up while avoiding unnecessary procedures and patient anxiety.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Cervical Cancer Screening Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.